

Please add new claims 21-40, as follows.

1 ~~506~~ --21. A nasally administered pharmaceutical formulation for treating sexual
2 dysfunction in a mammalian subject comprising a therapeutically effective amount of a dopamine
3 receptor agonist in a formulation for enhanced nasal delivery which yields enhanced nasal
4 absorption of said dopamine receptor agonist to produce a therapeutic result in said subject
5 within about 30 minutes or less.

1 22. The nasally administered pharmaceutical composition of Claim 21,
2 wherein administration of said dopamine receptor agonist in said formulation for enhanced nasal
3 delivery yields enhanced nasal absorption of said dopamine receptor agonist to produce a
4 therapeutic result in said subject within about 15 minutes or less.

1 23. A nasally administered pharmaceutical formulation for treating sexual
2 dysfunction in a mammalian subject comprising a therapeutically effective amount of a dopamine
3 receptor agonist in a formulation for enhanced nasal delivery which yields enhanced nasal
4 absorption of said dopamine receptor agonist resulting in a time to maximal plasma concentration
5 (tmax) of said dopamine receptor agonist in said subject of about 20 minutes or less.

1 24. The nasally administered pharmaceutical composition of Claim 23,
2 wherein administration of said dopamine receptor agonist in said formulation for enhanced nasal
3 delivery yields enhanced nasal absorption resulting in a time to maximal plasma concentration
4 (tmax) of said dopamine receptor agonist in said subject of about 15 minutes or less.

1 25. The nasally administered pharmaceutical composition of Claim 21,
2 wherein said subject is a female.

1 26. The nasally administered pharmaceutical composition of Claim 23,
2 wherein said subject is a female.

1 27. The nasally administered pharmaceutical composition of Claim 21,
2 wherein said therapeutic response is selected from an improvement of sexual desire in a male or
3 female subject, or amelioration of erectile dysfunction affecting an erectile tissue of a male or
4 female subject.

ADD NEW CLAIMS 21-40

1 28. The nasally administered pharmaceutical composition of Claim 23,
2 wherein said sexual dysfunction is selected from reduced sexual desire in a male or female
3 subject, or erectile dysfunction affecting an erectile tissue of a male or female subject..

1 ^{SUB}
2 ₀₃ 29. The nasally administered pharmaceutical composition of Claim 21,
3 wherein said dopamine receptor agonist is selected from the group consisting of apomorphine,
chemically modified equivalents and pharmaceutical salts thereof.

1 30. The nasally administered pharmaceutical composition of Claim 23,
2 wherein said dopamine receptor agonist is selected from the group consisting of apomorphine,
3 chemically modified equivalents and pharmaceutical salts thereof.

1 31. The nasally administered pharmaceutical composition of Claim 21,
2 wherein said dopamine receptor agonist is selected from the group consisting of apomorphine,
3 chemically modified equivalents and pharmaceutical salts thereof.

1 32. The nasally administered pharmaceutical composition of Claim 23,
2 wherein said dopamine receptor agonist is selected from the group consisting of apomorphine,
3 chemically modified equivalents and pharmaceutical salts thereof.

1 33. A method of increasing sexual desire or eliciting an erectile response in a
2 male or female mammalian subject comprising nasally administering a therapeutically effective
3 amount of a dopamine receptor agonist in a formulation for enhanced nasal delivery which yields
4 enhanced nasal absorption of said dopamine receptor agonist to produce a therapeutic result in
5 said subject within about 30 minutes or less.

1 34. The method of Claim 33, wherein administration of said dopamine
2 receptor agonist in said formulation for enhanced nasal delivery yields enhanced nasal absorption
3 of said dopamine receptor agonist to produce a therapeutic result in said subject within about 15
4 minutes or less.

1 35. A method of increasing sexual desire or eliciting an erectile response in a
2 male or female mammalian subject comprising nasally administering a therapeutically effective
3 amount of a dopamine receptor agonist in a formulation for enhanced nasal delivery which yields
4 enhanced nasal absorption of said dopamine receptor agonist resulting in a time to maximal

A2
Cm
10/10/2004
10:10:10

plasma concentration (tmax) of said dopamine receptor agonist in said subject of about 20 minutes or less.

36. The method of claim 35, wherein administration of said dopamine receptor agonist in said formulation for enhanced nasal delivery yields enhanced nasal absorption resulting in a time to maximal plasma concentration (tmax) of said dopamine receptor agonist in said subject of about 15 minutes or less.

37. The method of Claim 33, wherein said dopamine receptor agonist is selected from the group consisting of apomorphine, chemically modified equivalents and pharmaceutical salts thereof.

38. The method of Claim 35, wherein said dopamine receptor agonist is selected from the group consisting of apomorphine, chemically modified equivalents and pharmaceutical salts thereof.

39. A nasally administered pharmaceutical formulation for treating difficulty in achieving or inability of achieving orgasm in a female mammalian subject comprising a therapeutically effective amount of a dopamine receptor agonist in a formulation for enhanced nasal delivery which yields enhanced nasal absorption of said dopamine receptor agonist resulting in a time to maximal plasma concentration (tmax) of said dopamine receptor agonist in said subject of about 20 minutes or less.

40. A method of reducing difficulty in achieving or inability of achieving orgasm in a female mammalian subject comprising nasally administering a therapeutically effective amount of a dopamine receptor agonist in a formulation for enhanced nasal delivery which yields enhanced nasal absorption of said dopamine receptor agonist resulting in a time to maximal plasma concentration (tmax) of said dopamine receptor agonist in said subject of about 20 minutes or less, before, during or after sexual activity.--

REMARKS

Claims 21-40 are pending in the application. By this Preliminary Amendment, claims 1-20 have been canceled, without prejudice, and new claims 21-40 have been added to more distinctly claim certain aspects of the invention. All the claims added herein are fully supported by the specification, and no new matter has been added to the application. Entry of this Preliminary Amendment is respectfully requested.